In the face of abrupt weight loss, one of the most common consequences is hair loss, even after bariatric surgery. Losing ...

Eli Lilly's tirzepatide has been shown to significantly ... over the weekend and simultaneously published in the New England Journal of Medicine – also showed that treatment with the dual ...

For years, conventional wisdom has been that weight loss is a matter of willpower. Those who are overweight or obese just need to try harder to eat less and exercise more. But while diet and ...

The new weight loss drug offers promising results for those who are overweight or obese. Learn about how Zepbound works, its ...

Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

Researchers from the Rutgers Robert Wood Johnson Medical School and the Children's Hospital of Orange County discovered a ...

It is thought that neither semaglutide nor tirzepatide are very good ... The results have been published in the New England Journal of Medicine. Professors Wassilios Meissner and Olivier Rascol ...

In general, the injectable medications that are popular now, such as semaglutide and tirzepatide ... One study, published in the New England Journal of Medicine, found that participants who ...

Lilly’s oral GLP-1 challenger Lilly’s dual GIP/GLP-1 agonist Mounjaro (tirzepatide ... The study – published in the New England Journal of Medicine – revealed a 14.7% reduction in body ...

ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Plozasiran Update On January 17, 2025, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced that the U.S. Food and Drug Administration (FDA) ...

Research links weight loss medications like Ozempic and Zepbound to certain serious eye conditions. This association is being called “Ozempic blindness.” Experts are not entirely clear why ...

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese ...